# Invictus Therapeutics

Source: https://onco.cc/companies/invictus-therapeutics/  
OnCo record `invictus-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An Australian company developing medicines and supplements from tocotrienols, a form of vitamin E. Its cancer programme is a tocotrienol dissolved under the tongue, to be tested alongside standard treatment in advanced pancreatic cancer.

## Summary

Invictus Therapeutics Ltd, formerly VGI Health Technology Limited, is an Australian public company listed on the NSX. Its own announcements describe it as developing prescription medicines and dietary supplements based on tocotrienols, with patents on delivering them through the lining of the mouth, and list pancreatic adenocarcinoma among its targets, alongside muscle soreness, fatty liver disease, high cholesterol, high blood pressure and diabetes.

In January 2024 the company announced that its subsidiary, Invictus Ops Pty Ltd, had received ethics approval from the Human Research Ethics Committee of the Peter MacCallum Cancer Centre for a phase II study of IVB003, its sublingual tocotrienol, against placebo, each added to standard treatment in locally advanced or metastatic pancreatic cancer. The study was to enrol eighty patients at no fewer than eight Australian sites, with progression-free survival as the primary endpoint and Northern Health in Melbourne as the first site. No result has been published.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Invictus Therapeutics Ltd; VGI Health Technology Limited; VGI Health Technology; Invictus Ops Pty Ltd
- HQ: Sydney, NSW
- Type: biotech
- Ticker: NSX:VTL

## Notes

- Whether the IVB003 study has opened or enrolled could not be found. No ClinicalTrials.gov record names the company or the drug, and the Australian New Zealand Clinical Trials Registry refused a script (a Cloudflare challenge), so it was not searched.
- Founding year not stated. The Australian Business Register shows the entity active since 24 September 2004 under earlier names; that is the company's registration, not the start of its cancer work.
- Tocotrienols are also sold as supplements. A planned trial is not evidence that they help in pancreatic cancer.

## Sources

- NSX announcement: change of registered office, with company description (12 Dec 2025): https://www.nsx.com.au/ftp/news/021745076.PDF
- Company release: ethics approval for the phase II pancreatic cancer study (11 Jan 2024): https://abnnewswire.net/press/en/122891/VGI-Health-Technology-Limited-(NSX-VTL)-HREC-Approval-for-Phase-II-Clinical-Study.html
- Australian Business Register: ABN 35 111 082 485: https://abr.business.gov.au/ABN/View?abn=35111082485

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- drugs: [IVB003](https://onco.cc/drugs/ivb003/)

---
JSON: https://onco.cc/api/v1/entities/invictus-therapeutics.json